Repatha-when outcome trials come out this will>>>>

Not be good. Very few pts to go after and docs know where it belongs and right now it's has it's own TV show........The Biggest Loser....get it.....NBC....

 

Repatha outcomes will
be positive and statistically significant but it will not be clinically meaningful. IMPROVE-IT was this. Repatha outcomes may yield better than a 6% inprovement that IMPROVE-IT showed but will fall short of the 15-20% that entresto showed. I predict around a 8-12% max improvement. This will get it some better value at its current price but not enough to move the needle and expand the label meaningfully from a commercial perspective. Look for BD to be in a frantic over pay acquisition mode after the results are reveled.

 

Amgen corp dev is busy and looking harder now that the expectations is repatha will fail to meet expectations.

 

A RR of 25% or more would be compelling. I predict we will see much higher RRs in events and death. We will see.

 

Relative risk is not impressive if the absolute risk reduction is very small. Simple economics. Will the study be enough to prove that it is worth shelling out $14000 a year for Repatha?

 

At $14K the NNT (number needed to treat) to prevent one cardiovascular event better be very small. If not, get ready for a long and painful run with this drug.

 

Run from this company, run fast!

 

Why the delay?

 

reps are lazy...and dm's are mad. Thus a bad combo...oh by the way this drug a POS.

 

Tell ur DM to suck it